Participants 101 157 5
women with ErbB2 overexpressing metastatic breast cancer
Participants 569 598 4
women with HER2-positive MBC.
Participants 648 675 5
eligible patients (N = 112)
Participants 1850 1887 3
patients with HER2-overexpressing MBC
